ICU Medical, Inc. (ICUI)

From the record

ICU Medical, Inc.'s filings since 2017 show 2 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2018-03-02) (its current reports).

From the record

ICU Medical, Inc.'s 10 filed years say what it did: revenue went from $379 million in fiscal 2016 to $2.2 billion in fiscal 2025, up 21.8% a year; it rose in 6 of 9 years; the deepest fall was 10% from fiscal 2018 to fiscal 2019; net income was positive in 7 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, ICU Medical, Inc.'s diluted share count grew about 1.4% a year, and dividends and buybacks returned about 5% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 19 sales (9 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, ICU Medical, Inc. earned about 0 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 20 cents per dollar of everything the company owns. Leverage: it owed about 48 cents per dollar of assets, and net share issuance: its share count grew 2.1% over the year (the filed statements).

From the record

ICU Medical, Inc.'s standing among 109 graded names in its industry family: revenue of $2.2 billion in fiscal 2025 ranks in the top 13% by size; a net margin of 0% ranks in the top 32%; revenue growth of -0.7% a year over the last 3 filed years ranks in the bottom 22% (its annual reports).

From the record

ICU Medical, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Jain, Vivek (Chairman and CEO, as filed), filing under that title since 2014-02-21, 12.7 years (top 11% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 8.8 years (top 13%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (top 26%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

ICU Medical, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $308 million against debt of $1.3 billion leaves -23.7% of its assets as net cash, bottom 13% of its family; cash from operations less capital spending is 4.1% of revenue (top 32%); a gross margin of 36.8% (bottom 18%); research spending of 3.9% of revenue (bottom 18%) (its annual report).

From the record

ICU Medical, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -0.7% a year over the last three filed years against 21.8% over all 10, slowing (bottom 12% of its family); the newest year grew -6.3% (bottom 15%); research spending grew -2% a year (bottom 28%); capital spending grew -0.8% a year (bottom 50%) (its annual reports). ICU Medical, Inc. reported 3 product lines in fiscal 2025: Infusion Consumables at $1.1 billion (50%), Infusion Systems at $684 million (31%), Vital Care at $438 million (20%); 2 of 3 grew against the year before (its annual report).

From the record

ICU Medical, Inc.'s newest year against its own record: revenue of $2.2 billion in fiscal 2025 came in 8.4% below the $2.4 billion its prior three years' pace pointed to (bottom 38% of its family); net income of $732 thousand against a prior three-year average of $74 million (top 19%); a net margin of 0% against -3.2% before (bottom 35%) (its annual reports).